leisure time -WSS

leisure time

author：hotspot 2025-09-05 13:43:31 - browse：11

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Amazon expands telehealth clinic nationwide

WSS

Sage hopes for a blockbuster in antidepressant now before FDA

The high personal cost of affirmative action for Black doctors

The high personal cost of affirmative action for Black doctors

Lung cancer screening guidelines updated for cigarette smokers

Gene therapy’s promise and the high cost of hope

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Wikipedia

leisure time

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

Explaining an after

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

5 important ways Henrietta Lacks changed medical science

Affirmative action in medical school literally saved lives

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Bright Health sells Medicare Advantage business to Molina

After Sarepta trial failure, Duchenne families brace for more debate

Wikipedia

Medicare proceeds with plan to claw back hospital funds

5 important ways Henrietta Lacks changed medical science

Wildfire pollution widens asthma inequities on Long Island

Gene therapy’s promise and the high cost of hope

Sage hopes for a blockbuster in antidepressant now before FDA

Gene therapy’s promise and the high cost of hope

explore

entertainment

hotspot

hotspot